BioLineRx Ltd. (BLRX)
undefined
undefined%
At close: undefined
0.23
0.84%
After-hours Dec 13, 2024, 06:59 PM EST

Company Description

BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology.

The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia.

It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions.

The company has collaboration agreement with MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer; and licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010.

BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.

BioLineRx Ltd.
BioLineRx Ltd. logo
Country IL
IPO Date Jul 27, 2011
Industry Biotechnology
Sector Healthcare
Employees 79
CEO Philip A. Serlin CPA, M.B.A., CPA, MBA

Contact Details

Address:
Modi’in Technology Park
Hevel Modi'in,
IL
Website https://www.biolinerx.com

Stock Details

Ticker Symbol BLRX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001498403
CUSIP Number 09071M205
ISIN Number US09071M2052
Employer ID 00-0000000
SIC Code 2834

Key Executives

Name Position
Philip A. Serlin CPA, M.B.A., CPA, MBA Chief Executive Officer
Mali Zeevi CPA, CPA Chief Financial Officer
Dr. Ella Sorani Ph.D. Chief Development Officer
Holly W. May M.B.A. President of BioLineRx USA
John Lacey Head of Corporate Communications & Investor Relations
Raziel Fried Treasurer & Budgetary Control Director
Tsipi Keren-Lehrer B.Sc., L.L.B. Head of BD & Strategic Advisor

Latest SEC Filings

Date Type Title
Nov 25, 2024 6-K Filing
Nov 21, 2024 6-K Filing
Nov 21, 2024 424B5 Filing
Nov 12, 2024 6-K Filing
Nov 05, 2024 6-K Filing
Oct 16, 2024 6-K Filing
Oct 01, 2024 6-K Filing
Aug 19, 2024 6-K Filing
Aug 15, 2024 6-K Filing
Jun 18, 2024 6-K Filing